LABT
Income statement / Annual
Last year (2025), Lakewood-Amedex Biotherapeutics Inc.'s total revenue was $0.00,
and the percentage change from the previous year is not available.
In 2025, Lakewood-Amedex Biotherapeutics Inc.'s net income was -$3.85 M.
See Lakewood-Amedex Biotherapeutics Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
| Operating Revenue |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit |
$0.00
|
$0.00
|
$0.00
|
| Gross Profit Ratio |
0
|
0
|
0
|
| Research and Development Expenses |
$1.26 M
|
$2.10 M
|
$5.53 M
|
| General & Administrative Expenses |
$2.51 M
|
$1.92 M
|
$3.10 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$2.51 M
|
$1.92 M
|
$3.10 M
|
| Other Expenses |
$4.63 K
|
$6.30 K
|
$11.56 K
|
| Operating Expenses |
$3.77 M
|
$4.03 M
|
$8.64 M
|
| Cost And Expenses |
$3.77 M
|
$4.03 M
|
$8.64 M
|
| Interest Income |
$25.61 K
|
$142.60 K
|
$360.12 K
|
| Interest Expense |
$100.88 K
|
$5.00 K
|
$10.00 K
|
| Depreciation & Amortization |
$119.98 K
|
$118.59 K
|
$120.99 K
|
| EBITDA |
-$3.63 M |
-$4.73 M |
-$8.15 M |
| EBITDA Ratio |
0
|
0
|
0
|
| Operating Income Ratio |
0
|
0
|
0
|
| Total Other Income/Expenses Net |
-$75.27 K
|
-$828.59 K
|
$354.76 K
|
| Income Before Tax |
-$3.85 M
|
-$4.86 M
|
-$8.28 M
|
| Income Before Tax Ratio |
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
| Net Income |
-$3.85 M
|
-$4.86 M
|
-$8.28 M
|
| Net Income Ratio |
0
|
0
|
0
|
| EPS |
-2.76 |
-6.94 |
-11.84 |
| EPS Diluted |
-2.76 |
-6.94 |
-11.84 |
| Weighted Average Shares Out |
$1.39 M
|
$699.55 K
|
$699.55 K
|
| Weighted Average Shares Out Diluted |
$1.39 M
|
$699.55 K
|
$699.55 K
|
| Link |
|
|
|
